Peers: SANA KRYS BMRN INCY RYTM KYMR CRNX VKTX AXSM NBIX

| Held by: VTI IWM FESM VXF IWN IBB KOMP VTWO SURI SCHA

Index	RUT
Market Cap	514.02M
Enterprise Value	347.59M
Income	-152.64M
Sales	0.00M
Book/sh	2.69
Cash/sh	3.22
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	130
IPO	Feb 08, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.09
P/C	2.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.06
Current Ratio	9.06
Debt/Eq	0.20
LT Debt/Eq	0.19
Option/Short	Yes / Yes

EPS (ttm)	-2.94
EPS next Y	-3.03
EPS next Q	-0.69
EPS this Y	24.14%
EPS next Y	-9.89%
EPS next 5Y	14.07%
EPS past 3/5Y	-75.86% -56.27%
Sales past 3/5Y	- -
EPS Y/Y TTM	20.07%
Sales Y/Y TTM	-
EPS Q/Q	35.37%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	7.12% -

Insider Own	37.66%
Insider Trans	0.00%
Inst Own	47.12%
Inst Trans	5.20%
ROA	-68.40%
ROE	-87.24%
ROIC	-77.47%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.30%
SMA50	2.16%
SMA200	-0.56%
Trades

Shs Outstand	61.57M
Shs Float	38.55M
Short Float	21.21%
Short Ratio	8.16
Short Interest	8.18M
52W High	13.67 -39.20%
52W Low	3.50 137.48%
Volatility	7.30% 6.54%
ATR (14)	0.54
RSI (14)	52.56
Beta	1.98
Rel Volume	0.46
Avg Volume	1.00M
Volume	257,656

Perf Week	-7.13%
Perf Month	12.17%
Perf Quarter	-4.13%
Perf Half Y	5.08%
Perf YTD	-11.58%
Perf Year	115.89%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	30.40
Prev Close	8.42
Price	8.31
Change %	-1.29%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Aug-11-26 04:02PM	Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-27-26 08:00AM	Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel (GlobeNewswire) +6.88%
Jun-22-26 08:00AM	Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition (GlobeNewswire)
Jun-09-26 05:19PM	FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge)
Jun-03-26 08:00AM	Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis (GlobeNewswire)
08:00AM	Loading…
May-18-26 08:00AM	Kyverna Therapeutics Names Greg Martini as Chief Financial Officer (GlobeNewswire) -10.01%
May-14-26 08:00AM	Kyverna Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-13-26 06:27AM	Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B (BioPharma Dive) +5.38%
May-12-26 04:02PM	Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-04-26 08:00AM	Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer (GlobeNewswire)
Apr-21-26 06:45PM	Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting (GlobeNewswire) -13.69% +5.36%
Apr-20-26 08:00AM	Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks (GlobeNewswire) +13.29%
Apr-09-26 08:00AM	Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026 (GlobeNewswire)
Mar-26-26 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-05-26 04:21PM	Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 (GlobeNewswire) -5.41%
08:00AM	Loading…
Mar-03-26 08:00AM	Kyverna Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire) -5.76%
Feb-24-26 08:00AM	Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors (GlobeNewswire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-03-26 08:00AM	Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer (GlobeNewswire)
Jan-12-26 08:00AM	Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -7.30%
Dec-30-25 07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-17-25 09:24AM	Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock (GlobeNewswire) -32.52%
Dec-16-25 10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks) -5.36%
09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	Kyverna Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +23.23%
06:30AM	Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (GlobeNewswire)
03:41AM	Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease (BioPharma Dive)
Dec-14-25 02:30PM	Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome (GlobeNewswire)
Dec-12-25 07:30AM	2 Strong Buy Biotech Stocks With 208% to 329% Upside Potential (Barchart) +5.02%
04:05PM	Loading…
Nov-12-25 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.60%
Nov-10-25 08:00AM	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-03-25 08:00AM	Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance (GlobeNewswire)
Oct-29-25 06:30AM	Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 (GlobeNewswire) -5.78%
Oct-25-25 11:00AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 (GlobeNewswire)
Oct-22-25 08:00AM	Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis (GlobeNewswire) -6.58%
Oct-17-25 09:59AM	Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout (Insider Monkey) -5.42%
Sep-24-25 09:05AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS (GlobeNewswire)
Sep-15-25 01:02PM	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (GlobeNewswire)
Aug-28-25 08:00AM	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event (GlobeNewswire)
Aug-25-25 04:02PM	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire) +14.90%
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-29-25 10:23AM	Kyverna Appoints New CFO to Guide Next Growth Phase (Insider Monkey) -11.09%
08:30AM	Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise (PR Newswire)
Jun-30-25 09:00AM	Kyverna Therapeutics Announces Appointment of New Chief Financial Officer (PR Newswire) -6.40%
May-28-25 04:02PM	Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
May-13-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM	Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM	Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM	Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM	Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-03-25 04:05PM	Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference (PR Newswire) -8.80%
Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Executive ChairpersonMs. Christi L. Shaw

CEO & DirectorMr. Warner Biddle

M.D.Dr. Naji H. Gehchan M.B.A.

Chief Financial OfficerMr. Gregory Martini

Senior VP & Head of ResearchDr. Tom Van Blarcom Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KAREN WALKER	Officer	Apr 17 '26	Proposed Sale	9.53	10,000	95,300		Apr 17 04:37 PM
KAREN WALKER	Officer	Apr 14 '26	Proposed Sale	9.49	2,459	23,336		Apr 14 04:38 PM
DANIEL SPIEGELMAN	Director	Apr 07 '26	Proposed Sale	9.25	17,578	162,637		Apr 07 04:05 PM
DANIEL SPIEGELMAN	Director	Mar 31 '26	Proposed Sale	8.44	16,634	140,404		Mar 31 05:09 PM
SEIDENBERG BETH C	Director	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:43 AM
Westlake BioPartners Opportuni	10% Owner	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:42 AM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Option Exercise	4.83	23,998	115,910	46,634	Dec 17 08:30 PM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Sale	12.20	23,998	292,776	22,636	Dec 17 08:30 PM
KAREN WALKER	Officer	Dec 15 '25	Proposed Sale	8.78	23,998	210,702		Dec 15 04:16 PM

Open in Screener

ANNX

Annexon Inc

5.03

Aug 24 • 12:58 PM ET -0.04 (-0.78%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR RYTM INCY BMRN CRNX VKTX KRYS AXSM MDGL NBIX

| Held by: XBI VTI IWM VXF IWO IBB FESM VTWO SCHA IWC

Index	RUT
Market Cap	953.68M
Enterprise Value	769.09M
Income	-202.67M
Sales	0.00M
Book/sh	1.07
Cash/sh	1.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	96
IPO	Jul 24, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.72
P/C	4.56
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.53
Current Ratio	5.53
Debt/Eq	0.13
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	-1.15
EPS next Y	-1.00
EPS next Q	-0.28
EPS this Y	21.72%
EPS next Y	4.86%
EPS next 5Y	42.48%
EPS past 3/5Y	19.69% 20.17%
Sales past 3/5Y	- -
EPS Y/Y TTM	10.96%
Sales Y/Y TTM	-
EPS Q/Q	19.92%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-17.25% -

Insider Own	15.02%
Insider Trans	2.19%
Inst Own	89.37%
Inst Trans	15.37%
ROA	-79.38%
ROE	-105.26%
ROIC	-97.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.14%
SMA50	-6.32%
SMA200	-5.04%
Trades

Shs Outstand	174.60M
Shs Float	161.10M
Short Float	19.10%
Short Ratio	8.57
Short Interest	30.77M
52W High	7.18 -29.94%
52W Low	2.03 147.81%
Volatility	5.42% 5.85%
ATR (14)	0.33
RSI (14)	42.95
Beta	1.22
Rel Volume	0.75
Avg Volume	3.59M
Volume	1,491,846

Perf Week	-1.94%
Perf Month	-3.63%
Perf Quarter	-5.26%
Perf Half Y	2.87%
Perf YTD	0.21%
Perf Year	117.77%
Perf 3Y	69.95%
Perf 5Y	-69.95%
Perf 10Y	-
Recom	1.40
Target Price	15.71
Prev Close	5.07
Price	5.03
Change %	-0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-26	Upgrade	Citizens	Mkt Underperform → Mkt Perform
Jul-21-26	Initiated	Citizens	Mkt Underperform	$3
May-12-26	Initiated	Goldman	Neutral	$7
Dec-23-25	Initiated	Chardan Capital Markets	Buy	$16
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Aug-17-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-26 04:56PM	Annexon, Inc. Q2 2026 Earnings Call Summary (Moby)
07:33AM	Annexon shares fall as second-quarter loss exceeds Wall Street forecasts (InvestorsHub)
06:05AM	Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones (GlobeNewswire)
06:00AM	Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study (GlobeNewswire)
04:05PM	Loading…
Aug-10-26 04:05PM	Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors (GlobeNewswire)
Aug-06-26 08:00AM	Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week (GlobeNewswire)
Jul-30-26 04:01PM	Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance (GlobeNewswire) +8.44%
Jul-16-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.38%
Jul-14-26 04:05PM	Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 (GlobeNewswire) +17.12%
Jun-16-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.29%
May-27-26 08:00AM	Annexon to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-18-26 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-26 04:01PM	Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire)
May-06-26 08:00AM	Annexon to Present at the Bank of America Securities Health Care Conference 2026 (GlobeNewswire)
04:05PM	Loading…
Apr-08-26 04:05PM	Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-26 08:00PM	Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High? (Quartz)
Mar-30-26 04:01PM	Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +11.69%
Mar-16-26 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 05:48AM	Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference (MarketBeat)
Feb-24-26 08:00AM	Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-17-26 08:00AM	Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy (GlobeNewswire)
Jan-16-26 05:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-26 05:10PM	Annexon Maps Pivotal 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead (MarketBeat) +7.92% -7.78%
Jan-12-26 07:00AM	Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 (GlobeNewswire) +5.90%
Jan-08-26 08:00AM	Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barre Syndrome (GlobeNewswire)
Jan-07-26 04:05PM	Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.43%
Dec-23-25 08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-18-25 01:14AM	Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development (Insider Monkey)
Dec-16-25 07:31PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:26AM	Loading…
Nov-29-25 01:26AM	Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement (Insider Monkey)
Nov-14-25 04:01PM	Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million (GlobeNewswire) +11.44%
Nov-12-25 10:55PM	Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.63%
04:12PM	Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-10-25 04:05PM	Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire)
Sep-30-25 11:41AM	Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition (Insider Monkey)
Aug-27-25 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.81%
Aug-14-25 04:05PM	Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -8.46%
Aug-11-25 07:29AM	Annexon announces EMA selection of vonaprument for PDC pilot participation (Pharmaceutical Business Review)
Aug-07-25 04:30PM	Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy (GlobeNewswire)
Jul-24-25 07:00AM	Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
Jun-18-25 04:05PM	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) (GlobeNewswire)
May-29-25 04:05PM	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.39% -6.42%
May-19-25 04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-16-25 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
May-12-25 08:00AM	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +10.62%
May-09-25 05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire) -5.88%
05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire)
May-07-25 08:00AM	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress (GlobeNewswire)
Apr-16-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-15-25 07:12AM	Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (Seeking Alpha)
Apr-10-25 09:24AM	Why Annexon Inc. (ANNX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 03:20PM	Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder (Benzinga) -7.79%
Apr-08-25 04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -5.52%
04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Apr-03-25 06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barre Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -6.63% -7.65%
06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77% -9.09%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-03-25 08:00AM	Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -9.47%
Feb-26-25 04:05PM	Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

J.D.Mr. Douglas E. Love Esq.

Executive VPDr. Ted Yednock Ph.D.

Chief Scientific Officer & Executive VPDr. Dean R. Artis Ph.D.

Chief Human Resources OfficerMs. Linda A. Fitzpatrick

Executive VP & Chief Business OfficerMr. Michael Overdorf M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WIGGANS THOMAS G	Former Director	Aug 13 '26	Proposed Sale	5.30	2,000	10,596		Aug 13 03:34 PM
WIGGANS THOMAS G	Former Director	Jul 15 '26	Proposed Sale	6.32	2,000	12,630		Jul 15 04:19 PM
WIGGANS THOMAS G	Former Director	Jul 14 '26	Proposed Sale	5.61	1,000	5,605		Jul 14 01:56 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jun 11 '26	Option Exercise	1.85	30,646	56,698	184,807	Jun 15 04:15 PM
Satter Muneer A	Director	May 28 '26	Buy	5.41	613,497	3,319,019	10,342,134	May 29 05:21 PM
Carson William H.	Director	May 11 '26	Buy	5.78	8,000	46,240	78,405	May 13 04:30 PM
Carson William H.	Director	Apr 10 '26	Buy	6.20	8,000	49,600	70,405	Apr 14 04:16 PM
Carson William H.	Director	Mar 10 '26	Buy	5.67	8,000	45,360	62,405	Mar 12 04:31 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Mar 02 '26	Sale	5.43	5,820	31,603	123,582	Mar 04 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Mar 02 '26	Sale	5.42	4,339	23,517	182,625	Mar 04 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Mar 02 '26	Sale	5.42	5,566	30,168	154,161	Mar 04 04:30 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Mar 02 '26	Sale	5.43	5,894	32,004	180,093	Mar 04 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Mar 02 '26	Sale	5.42	5,565	30,162	170,700	Mar 04 04:30 PM
Yednock Ted	Officer	Mar 02 '26	Proposed Sale	5.42	5,566	30,181		Mar 02 05:05 PM
ARTIS DEAN RICHARD	Officer	Mar 02 '26	Proposed Sale	5.43	5,894	31,980		Mar 02 04:41 PM
Overdorf Michael	Officer	Mar 02 '26	Proposed Sale	5.42	4,339	23,530		Mar 02 04:16 PM
Dananberg Jamie	Officer	Mar 02 '26	Proposed Sale	5.43	5,820	31,579		Mar 02 04:05 PM
Lew Jennifer	Officer	Mar 02 '26	Proposed Sale	5.42	5,565	30,178		Mar 02 04:02 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '26	Sale	5.10	5,290	26,979	73,152	Feb 20 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	5.11	7,851	40,119	113,765	Feb 20 04:30 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '26	Sale	5.10	5,290	26,979	123,487	Feb 20 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '26	Sale	5.11	7,857	40,149	97,227	Feb 20 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '26	Sale	5.10	6,225	31,747	124,464	Feb 20 04:30 PM
Lew Jennifer	Officer	Feb 18 '26	Proposed Sale	5.11	7,851	40,119		Feb 18 03:39 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '26	Proposed Sale	5.10	5,290	26,990		Feb 18 03:38 PM
Yednock Ted	Officer	Feb 18 '26	Proposed Sale	5.11	7,857	40,122		Feb 18 03:29 PM
Overdorf Michael	Officer	Feb 18 '26	Proposed Sale	5.10	6,225	31,764		Feb 18 03:20 PM
Dananberg Jamie	Officer	Feb 18 '26	Proposed Sale	5.10	5,290	26,990		Feb 18 03:11 PM
Carson William H.	Director	Dec 30 '25	Buy	5.02	4,115	20,657	54,405	Jan 02 04:30 PM
Choi Jung	Director	Dec 01 '25	Buy	4.19	33,000	138,270	33,000	Dec 03 04:30 PM
Carson William H.	Director	Dec 01 '25	Buy	4.47	4,115	18,394	50,290	Dec 03 04:30 PM
Satter Muneer A	Director	Nov 21 '25	Buy	4.28	422,613	1,808,784	9,728,637	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 20 '25	Buy	4.48	400,000	1,792,000	9,306,024	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 19 '25	Buy	3.94	500,000	1,970,000	8,906,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 18 '25	Buy	3.18	500,000	1,590,000	8,406,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 17 '25	Buy	2.99	500,000	1,495,000	7,906,024	Nov 19 09:00 PM
Carson William H.	Director	Oct 30 '25	Buy	3.17	4,115	13,045	46,175	Oct 31 04:15 PM
Carson William H.	Director	Sep 30 '25	Buy	3.05	4,115	12,551	42,060	Oct 02 04:17 PM
Carson William H.	Director	Sep 02 '25	Buy	2.09	4,115	8,600	37,945	Sep 04 04:30 PM

KYTX

Kyverna Therapeutics Inc

ANNX

Annexon Inc

Upgrade your Finviz experience